AI Insight
This article discusses microablative fractional radiofrequency as a treatment approach for genitourinary syndrome of menopause (GSM) in postmenopausal women. GSM encompasses genital changes, sexual discomfort, and urinary issues that commonly occur during the menopause transition. The study examines the potential tissue effects of this radiofrequency-based intervention as an alternative or complement to existing hormone and nonhormone treatments.
Why it matters
This research addresses quality of life issues affecting a significant portion of postmenopausal women who experience GSM symptoms. Understanding the tissue-level effects of radiofrequency treatment could provide clinicians with additional evidence-based options for managing these common menopausal symptoms, particularly for women who cannot or prefer not to use hormone therapy.
Understand the Science
The menopause transition is often associated with genital changes, sexual discomfort and urinary issues—symptoms that collectively are known as the genitourinary syndrome of menopause (GSM). Hormone and nonhormone treatments are available to manage these symptoms.
Source: Potential tissue effects: Microablative fractional radiofrequency in postmenopausal women